Pharmacokinetics and Safety of a Single Oral Dose of Once-Daily Alfuzosin, 10 mg, in Male Subjects with Mild to Severe Renal Impairment-Reference-Cited by-同舟云学术

Pharmacokinetics and Safety of a Single Oral Dose of Once-Daily Alfuzosin, 10 mg, in Male Subjects with Mild to Severe Renal Impairment

Published:2002-12 Issue:12 Volume:42 Page:1311-1317
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:

Author:

Marbury Thomas C.,Blum Robert A.,Rauch Clémence,Pinquier Jean-Louis

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference30 articles.

1. Alfuzosin for treatment of benign prostatic hypertrophy;Jardin;Lancet,1991

2. Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 12-18 month assessment;Jardin;Br J Urol,1993

3. Comparative alpha-1 adrenoceptor subtype selectivity and functional uroselectivity of alpha-1 adrenoreceptor antagonists;Martin;J Pharmacol Exp Ther,1997

4. Relationship between the effects of alfuzosin on rat urethral and blood pressures and its tissue concentrations;Martin;Life Sci,1998

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recommandations françaises du Comité de transplantation de l’association française d’urologie (CTAFU) : symptômes du bas appareil urinaire et incontinence urinaire chez le patient transplanté ou en attente de transplantation rénale;Progrès en Urologie;2021-01

2. Medication burden and inappropriate prescription risk among elderly with advanced chronic kidney disease;BMC Geriatrics;2020-03-04

3. Troubles du bas appareil urinaire et de la statique pelvienne chez les candidats et receveurs d’une transplantation rénale;Progrès en Urologie;2016-11

4. The Effects of CKD on Cytochrome P450–Mediated Drug Metabolism;Advances in Chronic Kidney Disease;2016-03

5. Combining benefits of an adrenergic and a muscarinic blocker in a single formulation – A pharmacokinetic evaluation;Regulatory Toxicology and Pharmacology;2013-11